DIRECT MEDICAL COSTS IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): A REAL-WORLD EVIDENCE FROM FOUR CENTERS IN COLOMBIA
Author(s)
Claudia A. López-Cabra, MD, MSc1, Jose Daza-Vergara, MD, MSc2, Uriel Palacios Barahona, PhD2, Manuel R. Roa, MD, MSc1, Fernando E. Salcedo Mejía, BEc, MSc3, Lina M. Moyano, BEcon4, Rosmery V. Barroso, BEcon4, Liliana Torres, MD, MSc1, RAY MANNEH, MD, Oncologist5, Sergio I. Prada, PhD6, Angela Maria Paredes, MD7, Nelson R. Alvis Zakzuk, MBA4, Nelson José Alvis Zakzuk, MSc8;
1Bayer, Bogota, Colombia, 2Hospital Universitario Mayor Mederi - Universidad del Rosario, Bogota, Colombia, 3ALZAK - Universidad Tecnologica de Bolivar, Cartagena, Colombia, 4ALZAK, Cartagena, Colombia, 5Sociedad de Oncologia y Hematologia del Cesar, Valledupar, Colombia, 6Fundación Valle del Lili - Universidad ICESI Centro PROESA, Cali, Colombia, 7CEO Grupo Uroexpertos SAS, Medellin, Colombia, 8Universidad de la Costa,, Barranquilla, Colombia
1Bayer, Bogota, Colombia, 2Hospital Universitario Mayor Mederi - Universidad del Rosario, Bogota, Colombia, 3ALZAK - Universidad Tecnologica de Bolivar, Cartagena, Colombia, 4ALZAK, Cartagena, Colombia, 5Sociedad de Oncologia y Hematologia del Cesar, Valledupar, Colombia, 6Fundación Valle del Lili - Universidad ICESI Centro PROESA, Cali, Colombia, 7CEO Grupo Uroexpertos SAS, Medellin, Colombia, 8Universidad de la Costa,, Barranquilla, Colombia
Presentation Documents
OBJECTIVES: To estimate the direct medical costs of patients diagnosed with metastatic prostate cancer in the hormone-sensitive (mHSPC) and castration-resistant (mCRPC) stages across four healthcare centers in Colombia
METHODS: A retrospective, cross-sectional macro-costing study was conducted using HealthCare Delivery Records, billing/invoicing and pharmacy records from centers in Bogota, Apartado, Cali, and Valledupar between 2021-2024. Patients treated with chemotherapy plus antiandrogens and/or bone protectors and/or reported metastasis were classified as having metastatic disease. Patients treated with chemotherapy plus enzalutamide or abiraterone were categorized as having mCRPC. Patients who reported treatment with radiotherapy (enzalutamide/bicalutamide/apalutamide) or (orchidectomy + antiandrogens) were categorized as having hormone-sensitive metastatic disease (mHSPC). Direct medical costs were estimated by multiplying healthcare resource utilization frequencies with national tariffs and market prices. All costs were projected to March 2025 using the Colombian healthcare consumer price index and converted to USD (exchange rate: 4,192.57 COP). Finally, adjustments for differences in average cost estimates were made based on identifiable characteristics. A generalized linear model with a gamma distribution was used to estimate the adjusted cost ratios between the disease stages
RESULTS: A total of 268 patients with metastasis were included. The average annual direct medical cost per metastatic patient was US$19,164.5 (95% CI:US$15,524.5-US$22,804.6). Compared with non-metastatic patients, metastatic patients showed significantly higher utilization of medications (3.15-fold increase, p<0.01), laboratory and imaging services (1.77-fold increase, p<0.01), outpatient specialist visits (1.25-fold increase, p<0.01), and hospitalizations (2.3-fold increase, p<0.01). Among subgroups, the average adjusted annual cost for mHSPC patients was $9,266.11 (95% CI:$1,452.04-$22,375.81), while mCRPC patients reported substantially higher costs, averaging $26,641.13 (95% CI:$9,983.32-$71,093.56)
CONCLUSIONS: The average costs of the castration-resistant group were 2.8 times higher than those of the hormone-sensitive group for patients with metastatic prostate cancer. Avoiding/delaying progression to a castration-resistant state is important for the survival of patients and the health system
METHODS: A retrospective, cross-sectional macro-costing study was conducted using HealthCare Delivery Records, billing/invoicing and pharmacy records from centers in Bogota, Apartado, Cali, and Valledupar between 2021-2024. Patients treated with chemotherapy plus antiandrogens and/or bone protectors and/or reported metastasis were classified as having metastatic disease. Patients treated with chemotherapy plus enzalutamide or abiraterone were categorized as having mCRPC. Patients who reported treatment with radiotherapy (enzalutamide/bicalutamide/apalutamide) or (orchidectomy + antiandrogens) were categorized as having hormone-sensitive metastatic disease (mHSPC). Direct medical costs were estimated by multiplying healthcare resource utilization frequencies with national tariffs and market prices. All costs were projected to March 2025 using the Colombian healthcare consumer price index and converted to USD (exchange rate: 4,192.57 COP). Finally, adjustments for differences in average cost estimates were made based on identifiable characteristics. A generalized linear model with a gamma distribution was used to estimate the adjusted cost ratios between the disease stages
RESULTS: A total of 268 patients with metastasis were included. The average annual direct medical cost per metastatic patient was US$19,164.5 (95% CI:US$15,524.5-US$22,804.6). Compared with non-metastatic patients, metastatic patients showed significantly higher utilization of medications (3.15-fold increase, p<0.01), laboratory and imaging services (1.77-fold increase, p<0.01), outpatient specialist visits (1.25-fold increase, p<0.01), and hospitalizations (2.3-fold increase, p<0.01). Among subgroups, the average adjusted annual cost for mHSPC patients was $9,266.11 (95% CI:$1,452.04-$22,375.81), while mCRPC patients reported substantially higher costs, averaging $26,641.13 (95% CI:$9,983.32-$71,093.56)
CONCLUSIONS: The average costs of the castration-resistant group were 2.8 times higher than those of the hormone-sensitive group for patients with metastatic prostate cancer. Avoiding/delaying progression to a castration-resistant state is important for the survival of patients and the health system
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE142
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology